Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $23

Moomoo NewsApr 8 21:31 ET · Ratings

Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Dow JonesApr 8 16:05 ET

Artiva Biotherapeutics Price Target Maintained With a $23.00/Share by Needham

Dow JonesApr 8 08:53 ET · Ratings

Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support

TipRanksApr 8 06:57 ET

12 Health Care Stocks Moving In Monday's Intraday Session

BenzingaApr 7 13:05 ET

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswireMar 31 16:05 ET